Academic Journal
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
العنوان: | PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting |
---|---|
المؤلفون: | Pizzuti, Laura, Krasniqi, Eriseld, Sperduti, Isabella, Barba, Maddalena, Gamucci, Teresa, Mauri, Maria, Veltri, Enzo Maria, Meattini, Icro, Berardi, Rossana, Di Lisa, Francesca Sofia, Natoli, Clara, Pistelli, Mirco, Iezzi, Laura, Risi, Emanuela, D'Ostilio, Nicola, Tomao, Silverio, Ficorella, Corrado, Cannita, Katia, Riccardi, Ferdinando, Cassano, Alessandra, Bria, Emilio, Fabbri, Maria Agnese, Mazzotta, Marco, Barchiesi, Giacomo, Botticelli, Andrea, D'Auria, Giuliana, Ceribelli, Anna, Michelotti, Andrea, Russo, Antonio, Salimbeni, Beatrice Taurelli, Sarobba, Giuseppina, Giotta, Francesco, Paris, Ida, Saltarelli, Rosa, Marinelli, Daniele, Corsi, Domenico, Capomolla, Elisabetta Maria, Sini, Valentina, Moscetti, Luca, Mentuccia, Lucia, Tonini, Giuseppe, Raffaele, Mimma, Marchetti, Luca, Minelli, Mauro, Ruggeri, Enzo Maria, Scavina, Paola, Bacciu, Olivia, Salesi, Nello, Livi, Lorenzo, Tinari, Nicola, Grassadonia, Antonino, Fedele Scinto, Angelo, Rossi, Rosalinda, Valerio, Maria Rosaria, Landucci, Elisabetta, Stani, Simonetta, Fratini, Beatrice, Maugeri-Saccà, Marcello, De Tursi, Michele, Maione, Angela, Santini, Daniele, Orlandi, Armando, Lorusso, Vito, Cortesi, Enrico, Sanguineti, Giuseppe, Pinnarò, Paola, Cappuzzo, Federico, Landi, Lorenza, Botti, Claudio, Tomao, Federica, Cappelli, Sonia, Bon, Giulia, Pelle, Fabio, Cavicchi, Flavia, Fiorio, Elena, Foglietta, Jennifer, Scagnoli, Simone, Marchetti, Paolo, Ciliberto, Gennaro, Vici, Patrizia |
المساهمون: | Pizzuti, Laura, Krasniqi, Eriseld, Sperduti, Isabella, Barba, Maddalena, Gamucci, Teresa, Mauri, Maria, Veltri, Enzo Maria, Meattini, Icro, Berardi, Rossana, Di Lisa, Francesca Sofia, Natoli, Clara, Pistelli, Mirco, Iezzi, Laura, Risi, Emanuela, D'Ostilio, Nicola, Tomao, Silverio, Ficorella, Corrado, Cannita, Katia, Riccardi, Ferdinando, Cassano, Alessandra, Bria, Emilio, Fabbri, Maria Agnese, Mazzotta, Marco, Barchiesi, Giacomo, Botticelli, Andrea, D'Auria, Giuliana, Ceribelli, Anna, Michelotti, Andrea, Russo, Antonio, Salimbeni, Beatrice Taurelli, Sarobba, Giuseppina, Giotta, Francesco, Paris, Ida, Saltarelli, Rosa, Marinelli, Daniele, Corsi, Domenico, Capomolla, Elisabetta Maria, Sini, Valentina, Moscetti, Luca, Mentuccia, Lucia, Tonini, Giuseppe, Raffaele, Mimma, Marchetti, Luca, Minelli, Mauro, Ruggeri, Enzo Maria, Scavina, Paola, Bacciu, Olivia, Salesi, Nello, Livi, Lorenzo, Tinari, Nicola, Grassadonia, Antonino, Fedele Scinto, Angelo, Rossi, Rosalinda, Valerio, Maria Rosaria, Landucci, Elisabetta, Stani, Simonetta, Fratini, Beatrice, Maugeri-Saccà, Marcello, De Tursi, Michele, Maione, Angela, Santini, Daniele, Orlandi, Armando, Lorusso, Vito, Cortesi, Enrico, Sanguineti, Giuseppe, Pinnarò, Paola, Cappuzzo, Federico, Landi, Lorenza, Botti, Claudio, Tomao, Federica, Cappelli, Sonia, Bon, Giulia, Pelle, Fabio, Cavicchi, Flavia, Fiorio, Elena, Foglietta, Jennifer, Scagnoli, Simone, Marchetti, Paolo, Ciliberto, Gennaro, Vici, Patrizia |
سنة النشر: | 2021 |
المجموعة: | ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS) |
مصطلحات موضوعية: | HER2-positive, T-DM1, advanced breast cancer, lapatinib, pertuzumab, sequence |
الوصف: | Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-line pertuzumab-based regimen showed better PFS (p < 0.0001) and OS (p = 0.004) than those receiving other treatments. Median PFS and mOS from second-line starting were 8 and 28 months, without significant differences among various regimens. Pertuzumab-pretreated patients showed a mPFS and a mOS from second-line starting not significantly affected by type of second line, that is, T-DM1 or lapatinib/capecitabine (p = 0.80 and p = 0.45, respectively). Conversely, pertuzumab-naive patients receiving second-line T-DM1 showed a significantly higher mPFS compared with that of patients treated with lapatinib/capecitabine (p = 0.004). Median OS from metastatic disease diagnosis was higher in patients treated with trastuzumab-based first line followed by second-line T-DM1 in comparison to pertuzumab-based first-line and second-line T-DM1 (p = 0.003), although these data might be partially influenced by more favorable prognostic characteristics of patients in the pre-pertuzumab era. No significant differences emerged when comparing patients treated with 'old' or 'new' drugs (p = 0.43), even though differences in the length of the follow-up between the two cohorts should be taken into account. Conclusion: Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in ... |
نوع الوثيقة: | article in journal/newspaper |
وصف الملف: | ELETTRONICO |
اللغة: | English |
Relation: | info:eu-repo/semantics/altIdentifier/pmid/35173816; info:eu-repo/semantics/altIdentifier/wos/WOS:000723874100003; volume:13; firstpage:Art. N° 17588359211059873; numberofpages:18; journal:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY; https://hdl.handle.net/11564/807051; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85120166745 |
DOI: | 10.1177/17588359211059873 |
الاتاحة: | https://hdl.handle.net/11564/807051 https://doi.org/10.1177/17588359211059873 |
Rights: | info:eu-repo/semantics/openAccess |
رقم الانضمام: | edsbas.20B01A58 |
قاعدة البيانات: | BASE |
DOI: | 10.1177/17588359211059873 |
---|